129 related articles for article (PubMed ID: 10533487)
21. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
23. Farnesyltransferase inhibitors versus Ras inhibitors.
Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
[TBL] [Abstract][Full Text] [Related]
24. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.
Danesi R; Nardini D; Basolo F; Del Tacca M; Samid D; Myers CE
Mol Pharmacol; 1996 Jun; 49(6):972-9. PubMed ID: 8649357
[TBL] [Abstract][Full Text] [Related]
25. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway.
Reuveni H; Geiger T; Geiger B; Levitzki A
J Cell Biol; 2000 Dec; 151(6):1179-92. PubMed ID: 11121434
[TBL] [Abstract][Full Text] [Related]
26. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol.
Gelb MH; Tamanoi F; Yokoyama K; Ghomashchi F; Esson K; Gould MN
Cancer Lett; 1995 May; 91(2):169-75. PubMed ID: 7767906
[TBL] [Abstract][Full Text] [Related]
27. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).
Kawata S; Nagase T; Yamasaki E; Ishiguro H; Matsuzawa Y
Br J Cancer; 1994 Jun; 69(6):1015-20. PubMed ID: 8198962
[TBL] [Abstract][Full Text] [Related]
29. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
Girgert R; Hohnecker A; Wittrock J; Schweizer P
Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
[TBL] [Abstract][Full Text] [Related]
31. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides.
Sizemore N; Cox AD; Barnard JA; Oldham SM; Reynolds ER; Der CJ; Coffey RJ
Gastroenterology; 1999 Sep; 117(3):567-76. PubMed ID: 10464132
[TBL] [Abstract][Full Text] [Related]
33. Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors.
Eummer JT; Gibbs BS; Zahn TJ; Sebolt-Leopold JS; Gibbs RA
Bioorg Med Chem; 1999 Feb; 7(2):241-50. PubMed ID: 10218815
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics.
Cohen LH; Pieterman E; van Leeuwen RE; Overhand M; Burm BE; van der Marel GA; van Boom JH
Biochem Pharmacol; 2000 Oct; 60(8):1061-8. PubMed ID: 11007942
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein: farnesyl transferase.
Cohen LH; Pieterman E; van Leeuwen RE; Du J; Negre-Aminou P; Valentijn AR; Overhand M; van der Marel GA; van Boom JH
Biochem Pharmacol; 1999 Feb; 57(4):365-73. PubMed ID: 9933024
[TBL] [Abstract][Full Text] [Related]
36. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway.
Laezza C; Di Marzo V; Bifulco M
Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13646-51. PubMed ID: 9811854
[TBL] [Abstract][Full Text] [Related]
37. Kampanols: novel Ras farnesyl-protein transferase inhibitors from Stachybotrys kampalensis.
Singh SB; Zink DL; Williams M; Polishook JD; Sanchez M; Silverman KC; Lingham RB
Bioorg Med Chem Lett; 1998 Aug; 8(16):2071-6. PubMed ID: 9873488
[TBL] [Abstract][Full Text] [Related]
38. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.
Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Matsuzawa Y
Int J Cancer; 1996 Mar; 65(5):620-6. PubMed ID: 8598313
[TBL] [Abstract][Full Text] [Related]
40. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells.
Di Paolo A; Danesi R; Nardini D; Bocci G; Innocenti F; Fogli S; Barachini S; Marchetti A; Bevilacqua G; Del Tacca M
Br J Cancer; 2000 Feb; 82(4):905-12. PubMed ID: 10732765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
